Breast cancer frequently experiences oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B (PKB/AKT), and mammalian target of rapamycin (mTOR) pathway, which promotes tumor development, disease progression, and therapy resistance. Here, MTOR is linked to neoplasm.